[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-disease":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,79,103,123,147,188,216,239],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100629258","home-based-acute-care-for-older-persons-initiated-by-the-emergency-medical-and-ambulance-services---a-retrospective-observation-of-effects-on-healthcare-utilisation-and-mortality-100629258",false,"NCT07472335","Home-based Acute Care for Older Persons Initiated by the Emergency Medical and Ambulance Services - a Retrospective Observation of Effects on Healthcare Utilisation and Mortality","Inclusion Criteria:\n\n* Contact with the emergency number (112), followed by either a telephone assessment by the Emergency Medical Dispatch Centre or an in-home assessment by an ambulance nurse\n* Home-based acute care a weekday between 8 AM - 4 PM\n* Emergency-department care weeknight 4 PM - 8 AM or weekends\n* Registered residence in one of the municipalities of Gothenburg, Mölndal, Partille, or Härryda\n\nExclusion Criteria:\n\n* Immediate conditions requiring hospital care\n* Care at the emergency department or by a mobile primary care team occurring more than 24 hours after assessment by the Emergency Medical Dispatch Centre or ambulance services\n* Individuals who have already been assessed by a physician and\u002For have a written referral to the emergency department","ALL","75 Years",{"count":18,"type":19},5000,"ESTIMATED","OBSERVATIONAL","This observational study aims to examine outcomes of home-based acute care delivered by a mobile healthcare team in persons aged 75 years and older following an episode of acute illness.\n\nThe study will assess whether home-based acute care initiated by the emergency medical dispatch centre or ambulance services is non-inferior to emergency department care with regard to care needs and mortality.",[23,24,25,26,27,28,29,30,31,32],"Aged","Home Care, Hospital-Based","Home Care Services","Emergency Medical Dispatch Centre","Emergency Medical Services","Ambulances","Emergency Service, Hospital","Acute Disease","Mortality","Treatment Outcome","NOT_YET_RECRUITING","2026-03-10",{"date":36,"type":37},"2026-03-16","ACTUAL",{"date":39,"type":19},"2026-04-01",{"date":41,"type":19},"2027-12-31",{"name":43,"class":44},"Vastra Gotaland Region","OTHER_GOV",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100589039","phase-2-adjunctive-intra-arterial-tenecteplase-following-mechanical-thrombectomy-ally-ii-trial-100589039","NCT06949228","Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial","ALLY II TNK","Inclusion Criteria:\n\n1. Age 18-85\n2. Anterior circulation ischemic stroke symptoms with confirmed occlusion (ICA, M1, or M2) on angiogram and mechanical thrombectomy initiated within 24 hours since last known well\n3. Alberta Stroke Program Early CT Score (ASPECTS) Score ≥6 on baseline Non-contrast Head CT (NCCT)\n4. Post-mechanical thrombectomy with ≤5 device passes and mTICI grade 2b or higher.\n5. Ability to obtain signed informed consent prior to randomization from LAR or Subject\n\nExclusion Criteria:\n\n1. Premorbid modified Rankin scale (mRS) score \\>1\n2. Imaging evidence of hemorrhage or mass effect at baseline\n3. Platelet count \\\u003C100,000\n4. Active hemorrhagic diathesis, or known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency\n5. Active anticoagulation treatment with novel oral anticoagulant (NOACs) taken within the last 48 hours, or INR \\>1.7\n6. Patients requiring active treatment with dual antiplatelet agents (e.g. proximal cervical carotid artery stenting)\n7. Pregnant or lactating\n8. Previous known allergy to TNK\n9. Major surgery in past 30 days\n10. Patient is on or requires dialysis\n11. History of intracranial hemorrhage or serious head trauma at any time\n12. Any condition in the opinion of the enrolling physician that would preclude the patient from participating\n13. Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluation\n14. Severe, uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg) that is refractory to treatment\n15. History of acute ischemic stroke in the last 60 days and\u002For has received previous treatment with a thrombolytic within the last 90 days\n16. Presumed septic embolus; suspicion of bacterial endocarditis\n17. Suspicion of aortic dissection\n18. Intracranial neoplasm\n19. Any terminal medical condition with life expectancy less than 6 months\n20. Concurrent enrollment in another trial that could confound the results of this study\n21. Patient is unlikely to return for 90-day follow-up.\n22. Intravenous tissue plasminogen activator (tPA) administered concurrently with Intra-arterial TNK","18 Years","85 Years",{"count":56,"type":19},132,"INTERVENTIONAL",[59,60],"PHASE2","PHASE3","The study objective is to evaluate the safety and efficacy of Intra arterial (IA) Tenecteplase (TNK) as an adjunctive therapy in acute ischemic stroke (AIS) patients with large vessel occlusions (LVO) in the anterior circulation of Internal Carotid Artery (ICA), Middle Cerebral Arteries (M1 and M2) who achieve a reperfusion grade of Modified Treatment in Cerebral Ischemia Scale (mTICI) 2b or higher post-mechanical thrombectomy using Food and Drug Administration (FDA) approved devices.",[63,30],"Ischemic Stroke",[65,66,67],"Stroke","TNK","Thrombolytic","RECRUITING","2026-01-20",{"date":71,"type":37},"2026-01-21",{"date":73,"type":37},"2025-07-30",{"date":75,"type":19},"2028-05-30",{"name":77,"class":78},"ProMedica Health System","OTHER",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":45},"100614365","high-risk-antithrombotic-drugs-at-discharge-and-consultation-for-hemorrhagic-or-thromboembolic-events-in-the-emergency-department-100614365","NCT07278648","High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department","Prescription of High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department. Retrospective Cohort Study","Inclusion Criteria:\n\n* Patients discharged from the Emergency Department (ED) and acute care units with an electronic prescription for at least one anticoagulant medication (new or ongoing), identified with the following codes:\n\nB01AA - Vitamin K antagonists: warfarin and acenocoumarol\n\nB01AB - Heparin group: low-molecular weight heparins such as enoxaparin, tinzaparin, bemiparin, …\n\nB01AE - Direct thrombin inhibitors: dabigatran\n\nB01AF - Direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban\n\nExclusion Criteria:\n\n* Those who are not part of the CSAPG healthcare area.\n* Patients discharged from outpatient clinics, home hospitalization units, intermediate care, or residential facilities.",{"count":87,"type":19},150,"This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or hemorrhagic event related to the treatment.",[30],[91,92,93],"Antithrombotic Treatment","Hemorragic Event","Anticoagulants","2025-12-18",{"date":96,"type":37},"2025-12-24",{"date":98,"type":19},"2026-02-05",{"date":100,"type":19},"2026-03-01",{"name":102,"class":78},"Consorci Sanitari de l'Alt Penedès i Garraf",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":45},"100593493","is-a-positive-necpal-in-icu-patients-associated-with-higher-mortality-100593493","NCT07007156","Is a Positive NECPAL in ICU Patients Associated With Higher Mortality","Inclusion Criteria:\n\n* Patients who meet all of the following inclusion criteria may be included in the study:\n* Men and women aged 75 years or older.\n* Admission to the ICU of the study center.\n* Legal capacity to provide informed consent.\n* Signed informed consent for study inclusion, either by the participant or their legal representative.\n\nExclusion Criteria:\n\nParticipants who meet any of the following exclusion criteria may not be included in the study:\n\n-Death within the first 24 hours of ICU admission.",{"count":110,"type":19},199,"The aim of the present study is to evaluate the usefulness of the NECPAL scale in identifying Intensive Care Unit (ICU)-admitted patients at higher risk of dying within 90 days of ICU admission",[30],[30,114],"Intensive Care Unit","2025-12-01",{"date":117,"type":37},"2025-12-05",{"date":119,"type":37},"2025-06-12",{"date":121,"type":19},"2027-01",{"name":102,"class":78},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":57,"phases":133,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":45},"100540361","levels-of-diagnostic-and-therapeutic-intervention-in-hospitalized-patients-100540361","NCT06315842","Levels of Diagnostic and Therapeutic Intervention in Hospitalized Patients","Levels of Diagnostic and Therapeutic Intervention in Hospitalized Patients. Cluster-Randomized and Stepped-Wedge Clinical Trial","NIT","Inclusion Criteria:\n\n* Physician belonging to the non-surgical medical area.\n* Routine clinical activity on a hospital ward caring for hospitalized patients.\n\nExclusion Criteria:\n\n* Physician belonging to the Oncology-Hematology\u002FPalliative Care Hospitalization Unit.\n* Refusal to participate in the study.",{"count":132,"type":19},20,[134],"NA","The objective of this clinical trial is to investigate the impact of implementing a tool for adjusting the level of diagnostic and therapeutic intensity in the clinical practice of physicians attending hospitalized patients.\n\nThe goal of this clinical trial is to investigate the impact of a tool for adjusting diagnostic and therapeutic intensity in hospitalized patients. The main question it aims to answer is: Is there a difference in patient mortality when using the aforementioned tool? The participating physicians will be grouped into 4 groups (5 physicians each). Each group will progressively (every 3 months) incorporate the use of the aforementioned tool into their usual clinical practice.",[30],[138,139,140],"Patient Care Planning","Decision Making","Advance Care Planning",{"date":117,"type":37},{"date":143,"type":19},"2026-02",{"date":145,"type":19},"2027-08",{"name":102,"class":78},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":57,"phases":157,"briefSummary":158,"conditions":159,"keywords":169,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":45},"100566450","efficiency-of-the-medidux-smartphone-app-for-demission-management-in-patients-medicated-in-acute-admission-unit-aau-100566450","NCT06655337","Efficiency of the \"Medidux\" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU)","Efficiency of the \"Medidux\" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU): a Randomized Controlled Trial.","EffiDux","Inclusion Criteria:\n\n* Signed Informed Consent Form (ICF)\n* Age ≥ 18 years\n* (Self-)admission to the involved Acute Admissions Unit (AAU)\n* \"Lead symptom\" identified as coughing, back pain or abdominal discomfort\n* Participant within ESI triage system group 4 (standard) and 5 (non-urgent)\n* German-speaking\n* Ownership of a smartphone or other mobile device with iOS or Android operating system\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Participant whose compliance to the study's protocol, e.g. due to mental health problems, physical problems, or the private life situation, can be justifiably doubted\n* Participant with insufficient knowledge about the use of a smartphone or other mobile device with iOS or Android operating system\n* Participant already using or planning to use another comparable electronic patient-reported symptom monitoring system (e.g. CANKADO) during this trial",{"count":156,"type":19},417,[134],"The goal of this clinical trial is to evaluate whether the use of the medidux™ smartphone app can optimize post-discharge management for patients admitted to Acute Admission Units (AAU) with non-urgent health complaints. This trial includes adult patients (age ≥ 18) in Emergency Severity Index (ESI) triage system groups 4 (standard) or 5 (non-urgent), presenting with primary symptoms such as cough, back pain, or abdominal discomfort.\n\nThe main question it aims to answer is:\n\nCan the medidux™ app reduce the incidence of AAU readmissions, emergency hospitalizations, or consultations with other medical providers within 7 days after initial admission?\n\nResearchers will compare participants using the medidux™ app (intervention arm) with those receiving standard care (control arm) to observe potential differences in the rates of readmissions, emergency hospitalizations, and medical consultations.\n\nParticipants will:\n\n* use the medidux™ app to monitor their symptoms and vital parameters for 7 days after discharge (intervention arm).\n* receive follow-up consultations at day 7 and at day 28 to assess symptom progression and any healthcare interactions (both arms).",[30,160,161,162,163,164,165,166,167,168],"Acute Hospitalization","Coughing","Back Pain","Abdominal Pain (AP)","Patient Discharge","Patient Readmission","Mobile Health Apps","Mobile Health Technology (mHealth)","Patient Reported Outcome (PRO)",[30,164,165,161,162,170,171,172,173,174,175,176,177],"Abdominal Pain","Mobile Health Applications","Remote Monitoring","Post-discharge Care","Symptom Monitoring","Health Behaviour","Telemedicine","Randomized Controlled Trial","2025-09-29",{"date":180,"type":37},"2025-10-03",{"date":182,"type":37},"2025-09-28",{"date":184,"type":19},"2027-03-28",{"name":186,"class":187},"Mobile Health AG","INDUSTRY",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":15,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":57,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100585346","evaluation-of-a-residential-in-reach-program-in-regional-and-rural-australia-100585346","NCT06901167","Evaluation of a Residential In-Reach Program in Regional and Rural Australia","Evaluation of a Region-wide Residential In-Reach (RIR) Program in Regional and Rural Health Services: A Stepped-wedge Trial","Inclusion Criteria:\n\n* Health services that have emergency departments and\u002For emergency care centres that admit residents from residential aged care homes (RACH)\n* RACHs that do not currently have access to RIR programs\n* health service staff who have been involved with the set-up and delivery of the RIR program,\n* RACH staff who have experience of or accessing the RIR service for residents at least once,\n* residents living at a RACH who has experienced receiving medical care from the RIR program and can provide informed consent, or a family member of the resident,\n* general practitioners whose case load includes residents from RACHs.\n\nExclusion Criteria:\n\n• RACHs that already have access to a RIR program will be excluded","65 Years",{"count":197,"type":19},100,[134],"Residential In-Reach (RIR) programs are designed to provide responsive care for residents in residential aged care homes (RACH) with the aim of avoiding unnecessary hospital transfers. The evidence for their clinical and cost-effectiveness and implementation has been established in urban settings, but there is a small amount of low-quality evidence for rural and regional settings. The Grampians Region Health Service Partnership Resi-In-Reach Redesign Committee will be implementing a new RIR program to be offered to all RACHs in the Grampians region, this project aims to evaluate the clinical and cost-effectiveness of this program, and its implementation in the rural and regional setting. A stepped-wedge trial will be conducted so that as the RIR program is gradually rolled-out across the region, outcomes can be compared in the same facilities across time and between different facilities. The primary outcome measure will be presentation to emergency departments and urgent care centres, and data will also be collected on other clinical outcomes and barriers and enablers of implementing the program. It is anticipated that there will be a reduction in hospital presentations, and a range of barriers and enablers unique to the rural and regional setting will emerge.",[23,30],[202,203,204,205],"stepped-wedge trial","residential aged care home","residential in reach","hospital avoidance","2025-05-25",{"date":208,"type":37},"2025-05-30",{"date":210,"type":37},"2025-05-01",{"date":212,"type":19},"2026-06-30",{"name":214,"class":78},"Monash University",8,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":45},"100591701","a-long-term-observational-study-to-describe-the-use-of-vitamin-c-injektopas-75-g-in-patients-with-vitamin-c-deficiency-100591701","NCT06983847","A Long-term Observational Study to Describe the Use of Vitamin-C Injektopas® 7.5 g in Patients With Vitamin C Deficiency","Observational Study on Vitamin C-Injektopas® 7.5g in Patients With Vitamin C Deficiency Due to Acute and Chronic Diseases","Inclusion Criteria:\n\n* Patients with vitamin C deficiency\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Hypersensitivity to the active ingredient or any of the excipients\n* Oxalate urolithiasis\n* Iron storage disease (thalassemia, hemochromatosis, sideroblastic anemia) or recent red blood cell transfusion\n* Renal insufficiency\n* Glucose-6-phosphate dehydrogenase deficiency\u002Fdefect\n* Pregnant\u002Fbreastfeeding women","120 Years",{"count":225,"type":19},1000,"The goal of this observational study is to learn more about the disease and the symptoms where the product will use and in which patient groups. Further on, it is interesting to know clinical pictures, the symptoms improve. Patients with acute or chronical disease with vitamin c deficiency could be involved.\n\nThe main questions it aims to answer are:\n\n* how do the symptoms of the disease change\n* how is the tolerability",[228,229,30],"Deficiency, Vitamin C","Chronic Disease","2025-05-14",{"date":232,"type":37},"2025-05-21",{"date":234,"type":37},"2019-01-12",{"date":236,"type":19},"2028-11-14",{"name":238,"class":187},"Pascoe Pharmazeutische Praeparate GmbH",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":247,"targetDuration":249,"studyType":20,"phases":4,"briefSummary":250,"conditions":251,"keywords":270,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":45},"100409713","acutelines-a-large-data-biobank-of-acute-and-emergency-medicine-100409713","NCT04615065","Acutelines: a Large Data-\u002FBiobank of Acute and Emergency Medicine","Acutelines: a Large Biobank Aiming to Improve Early Recognition of Acute Diseases, Contribute to the Development of Personalized Medicine and Optimize Short- and Long-term Outcome","Acutelines","Inclusion Criteria, at least one of the following:\n\n* Triaged as one of highest two triage categories (red or orange) according to the Manchester triage system;\n* Triaged as the third highest triage category (yellow) and arrival by EMS of Helicopter Emergency Medical Service (HEMS;\n* Shock\n* Suspicion of sepsis (based on either physicians' suspicion, Sepsis-2 or Sepsis-3 criteria)\n* Acute kidney injury (AKI)\n* Anaphylactic reaction\n* Syncope\n* Intoxication\n* Thrombosis\n* Pulmonary embolism\n* Bleeding while using anti-coagulant drugs\n* Gastro-intestinal bleeding\n* Electrolyte disturbance\n\nExclusion Criteria:\n\n* Referred for organ transplantation as recipient\n* Transfer from other hospital\n* Accidental contact patient material (i.e. internal work-related accident)\n\nWhile data- and imaging will be collected from all these patients, biomaterials will only be collected from patients fulfilling the first criterion (i.e. triaged as one of highest two triage categories \\[red or orange\\] according to the Manchester triage system) and from patients with shock or a suspicion of sepsis.",{"count":248,"type":19},35000,"5 Years","Research in acute care faces many challenges, including enrollment challenges, legal limitations in data sharing, limited funding, and lack of singular ownership of the domain of acute care. To overcome some of these challenges, the Center of Acute Care of the University Medical Center Groningen in the Netherlands, has established a de novo data-, image- and biobank named \"Acutelines\". Acutelines is initiated to improve recognition and treatment of acute diseases and obtain insight in the consequences of acute diseases, including factors predicting its outcome. Thereby, Acutelines contributes to development of personalized treatment and improves prediction of patient outcomes after an acute admission.",[30,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269],"Sepsis","Pneumonia","Frailty","Complication of Treatment","Pulmonary Embolism","Thrombosis","Acute Kidney Injury","Electrolyte Disturbance","Hemorrhage","Shock","Polypharmacy","Intoxication by Drug","Emergencies","Urinary Tract Infections","Skin Infection","Syncope","Anaphylaxis","Dyspnea",[271,252,272,273,274,275,276,277,278,279,280,281,31,282,283,284,285,286,287,288,289,290,291],"Acute disease","Emergency Medical Service (EMS)","Outcome","Precision medicine","Personalized medicine","Emergency medicine","Multidisciplinary","General practitionar","Pharmacy","Hospitalization","Health insurance","Quality of life (QoL)","Overcrowding","Patient logistics","Point-of-care ultrasound (POCUS)","Helicopter Emergency Medical Service (HEMS)","Biobank","Databank","Electrophysiological waveforms","Electrocardiogram (ECG)","Plethysmogram","2024-06-12",{"date":294,"type":37},"2024-06-13",{"date":296,"type":37},"2020-09-01",{"date":298,"type":19},"2030-09-01",{"name":300,"class":78},"University Medical Center Groningen"]